First experience of the AML-Berlin-Frankfurt-Münster group in pediatric patients with standard-risk acute promyelocytic leukemia treated with arsenic trioxide and all-trans retinoid acid-Reference-Cited by-同舟云学术

First experience of the AML-Berlin-Frankfurt-Münster group in pediatric patients with standard-risk acute promyelocytic leukemia treated with arsenic trioxide and all-trans retinoid acid

Published:2017-01-23 Issue:8 Volume:64 Page:e26461
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Creutzig Ursula¹,Dworzak Michael N.²,Bochennek Konrad³,Faber Jörg⁴,Flotho Christian⁵,Graf Norbert⁶,Kontny Udo⁷,Rossig Claudia⁸,Schmid Irene⁹,von Stackelberg Arend¹⁰,Mueller Jans-Enno¹¹,von Neuhoff Christine¹¹,Reinhardt Dirk¹¹,von Neuhoff Nils¹¹

Affiliation:

1. Department of Pediatric Hematology/Oncology; Hannover Medical School, Children's Hospital; Hannover Germany

2. Department of Pediatrics; St. Anna Children's Hospital and Children's Cancer Research Institute, Medical University of Vienna; Vienna Austria

3. Division for Pediatric Hematology and Oncology; Johann Wolfgang Goethe-University; Frankfurt Germany

4. Department of Pediatric Hematology/Oncology; University Medicine of the Johannes Gutenberg-University Mainz; Mainz Germany

5. Division of Pediatric Hematology/Oncology; University Medical Center; Freiburg Germany

6. Department of Pediatric Oncology/Hematology; Saarland University; Homburg Germany

7. Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Medical Faculty; RWTH Aachen University; Aachen Germany

8. Department of Pediatric Hematology and Oncology; University Children's Hospital Muenster; Muenster Germany

9. Department of Pediatric Hematology and Oncology, Dr. von Hauner Children`s Hospital; Ludwig-Maximilians-University Munich; Munich Germany

10. Department of Pediatric Oncology/Hematology; Charité University Medical Center Berlin; Berlin Germany

11. Department of Pediatric Hematology-Oncology; University of Duisburg-Essen; Essen Germany

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology, and Child Health

Reference11 articles.

1. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia;Lo-Coco;N Engl J Med.,2013

2. The 12-year follow-up of survival, chronic adverse effects, and retention of arsenic in patients with acute promyelocytic leukemia;Zhu;Blood.,2016

3. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial;Burnett;Lancet Oncol.,2015

4. Randomized phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: health-related quality-of-life outcomes;Efficace;J Clin Oncol.,2014

5. Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia;Zhou;Blood.,2010

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term outcome of children with acute promyelocytic leukemia: a randomized study of oral versus intravenous arsenic by SCCLG-APL group;Blood Cancer Journal;2023-12-05

2. Differentiation syndrome and coagulation disorder — comparison between treatment with oral and intravenous arsenics in pediatric acute promyelocytic leukemia;Annals of Hematology;2023-05-18

3. Chemotherapy-free treatment for acute promyelocytic leukemia: the pediatric view of a revolutionary tale;Frontiers in Oncology;2023-04-14

4. Long-Term Outcome of Children with Acute Promyelocytic Leukaemia: A Randomised Study of Oral Versus Intravenous Arsenic by SCCLG-APL Group;2023

5. Childhood acute promyelocytic leukemia in a pediatric cancer referral center in Baghdad, Iraq. Improved results with ATRA extended consolidation;Leukemia & Lymphoma;2022-08-01